MAYZENT 0.25 MG
SIPONIMOD : 0.25 MG · DIN 02496429 · NOVARTIS PHARMACEUTICALS CANADA INC
Health Canada status: MARKETED
What is MAYZENT?
MAYZENT 0.25 MG contains SIPONIMOD : 0.25 MG. It is listed in the Health Canada Drug Product Database under DIN 02496429, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 24-Apr-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MAYZENT used for?
Treatment of patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features, to delay the progression of physical disability.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02496429 |
|---|---|
| Brand name | MAYZENT |
| Generic / active ingredient | SIPONIMOD : 0.25 MG |
| Manufacturer | NOVARTIS PHARMACEUTICALS CANADA INC |
| Strength | 0.25 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L04AE03 SIPONIMOD |
| AHFS class | 90:04.16 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 24-Apr-2020 |
| Original market date | 2020-04-24 00:00:00 |
How is it administered?
Titration: Days 1-5 (0.25mg to 1.25mg). Maintenance: 2mg daily (1mg for CYP2C9*1*3 or *2*3). Take orally with or without food. First-dose monitoring required for certain cardiac conditions.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text snippet (section 11 is listed in TOC but content is missing), though typically requires specific conditions.
How is it supplied?
Starter packs of 12 tablets (0.25 mg). Maintenance: Cartons of 28 tablets (1 mg); Cartons of 14 or 28 tablets (2 mg).
Contraindications
Hypersensitivity to siponimod, peanut, or soya; CYP2C9*3*3 genotype; immunocompromised; severe active infections; active malignancies; recent (6 months) MI, unstable angina, stroke, TIA, or heart failure.
Warnings and precautions
Transient heart rate decrease/AV conduction delays; risk of infections; macular edema; liver injury; increased blood pressure; cutaneous malignancies; posterior reversible encephalopathy syndrome.
What can be used instead?
Other Canadian products sharing ATC code L04AE03 SIPONIMOD. 2 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MAYZENT | 2 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02496437 |
| MAYZENT | 1 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | APPROVED | DIN 02543370 |
Who else supplies SIPONIMOD worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SIPONIMOD appears in 32 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.